US2019127734A1PendingUtilityA1
Mir-29 mimics and uses thereof
Est. expirySep 8, 2034(~8.2 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 9/00A61P 27/02A61P 17/02A61P 13/12A61P 1/16A61P 11/00A61P 19/02C12N 2310/346C12N 2320/51C12N 2310/3231C12N 15/113C12N 2310/113A61K 31/7105A61K 9/0073C12N 2310/315A61K 31/713A61K 9/007C12N 2310/141C12N 2310/343A61K 9/0078A61K 9/0075
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.
Claims
exact text as granted — not AI-modified1 . A miR-29 mimetic compound comprising:
a first strand of about 23 to about 26 ribonucleotides comprising a mature miR-29a, miR-29b, or miR-29c sequence; and a second strand of about 22 to about 23 ribonucleotides comprising a sequence that is substantially complementary to the first strand and having at least one modified nucleotide, wherein the first strand has a 3′ nucleotide overhang relative to the second strand.
2 .- 29 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.